Boston Scientific Corp. Given “Neutral” Rating at Zacks (BSX)
Boston Scientific Corp. (NYSE:BSX)‘s stock had its “neutral” rating reiterated by Zacks in a research note issued to investors on Wednesday, Analyst Ratings Network.com reports. They currently have a $12.00 price objective on the stock. Zacks‘ price target points to a potential upside of 4.71% from the stock’s previous close.
Shares of Boston Scientific Corp. (NYSE:BSX) traded up 1.31% during mid-day trading on Wednesday, hitting $11.61. The stock had a trading volume of 6,063,716 shares. Boston Scientific Corp. has a one year low of $5.04 and a one year high of $12.16. The stock’s 50-day moving average is $11.45 and its 200-day moving average is $9.65. The company’s market cap is $15.591 billion.
Boston Scientific Corp. (NYSE:BSX) last released its earnings data on Thursday, July 25th. The company reported $0.18 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.10 by $0.08. The company had revenue of $1.81 billion for the quarter, compared to the consensus estimate of $1.78 billion. During the same quarter last year, the company posted $0.17 earnings per share. Boston Scientific Corp.’s revenue was down 1.0% compared to the same quarter last year. Analysts expect that Boston Scientific Corp. will post $0.44 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at CL King downgraded shares of Boston Scientific Corp. from a “buy” rating to a “neutral” rating in a research note to investors on Tuesday, September 10th. Separately, analysts at Barclays Capital reiterated a “buy” rating on shares of Boston Scientific Corp. in a research note to investors on Wednesday, September 4th. They now have a $12.00 price target on the stock. Finally, analysts at Credit Suisse raised their price target on shares of Boston Scientific Corp. from $11.00 to $12.00 in a research note to investors on Wednesday, September 4th. Fourteen analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $9.69.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.